Breaker Circuit Miniature 6KA 400V DC 2P System Solar PV Switch Air 50A Pole 2 Circuit Breakers


  1. Home
  2. Breaker Circuit Miniature 6KA 400V DC 2P System Solar PV Switch Air 50A Pole 2
  1. facebook
  2. twitter
  3. linkedin
  4. pinterest
DC 400V 6KA Miniature Circuit Breaker 2P 2 Pole 50A Air Switch PV Solar System
Condition: New: A brand-new, unused, unopened, undamaged item in its original packaging (where packaging is Current Rating: 50A
Bundle Listing: No Modified Item: No
Tripping Characteristics: Type C Country/Region of Manufacture: China
Voltage Rating: DC 400V Custom Bundle: No
Non-Domestic Product: No Mounting Style: DIN Rail Mounting
MPN:

Does Not Apply

Number of Poles: 2
Brand:

Unbranded

Breaking Capacity: 6KA
UPC:

Does not apply






published on tue nov 09 2021

Breaker Circuit Miniature 6KA 400V DC 2P System Solar PV Switch Air 50A Pole 2 Circuit Breakers

gandhi, s., klein, j., robertson, a., pena-hernandez, m. a.,

Breaker Circuit Miniature 6KA 400V DC 2P System Solar PV Switch Air 50A Pole 2 Circuit Breakers

lin, m. j., roychoudhury, p., lu, p., fournier, j., ferguson, d., mohamed bakhash, s. a., muenker, m. c., srivathsan, a., wunder, e. a., kerantzas, n., wang, w., pyle, a., wilen, c. b., ogbuagu, o., greninger ,, a. l., iwasaki, a., schulz, w. l., ko, a. i.

sars-cov-2 remdesivir resistance mutations have been generated in vitro but have not been reported in patients receiving treatment with the antiviral agent. we present a case of an immunocompromised patient with acquired b-cell deficiency who developed an indolent, protracted course of sars-cov-2 infection. remdesivir therapy alleviated symptoms and produced a transient virologic response, but her course was complicated by recrudescence of high-grade viral shedding. whole genome sequencing identified a mutation, e802d, in the nsp12 rna-dependent rna polymerase which was not present in pre-treatment specimens. in vitro experiments demonstrated that the mutation conferred a ~6-fold increase in remdesivir ic50 but resulted in a fitness cost in the absence of remdesivir. sustained clinical and virologic response was achieved after treatment with casirivimab-imdevimab. although the fitness cost observed in vitro may limit the risk posed by e802d,

, this case illustrates the importance of monitoring for remdesivir resistance and the potential benefit of combinatorial therapies in immunocompromised patients with sars-cov-2 infection.

509
1.2k
EVGENIA.RU RSS